Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | KMO | O15229 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624981 | 1.00 | TSHR (0.59) | TSHRMRGPRX4KMONOTUMPDK1 | |
| SCHEMBL375961 | 0.85 | TSHR (0.59) | TSHRNOTUMPDK1SRD5A2ALDH1A1 | |
| SCHEMBL30255650 | 0.85 | NOTUM (0.46) | TSHRMRGPRX4KMONOTUMPDK1 | |
| SCHEMBL9526608 | 0.85 | NOTUM (0.46) | TSHRMRGPRX4KMONOTUMPDK1 | |
| SCHEMBL10532934 | 0.85 | KMO (0.43) | TSHRMRGPRX4KMONOTUMPDK1 | |
| SCHEMBL24400223 | 0.85 | KMO (0.43) | TSHRMRGPRX4KMONOTUMPDK1 | |
| SCHEMBL5490305 | 0.84 | TAS1R3 (0.56) | MRGPRX4NOTUMMAPTRORC | |
| SCHEMBL313146 | 0.83 | KIF11 (0.54) | MRGPRX4KMONOTUMPDK1KDR | |
| SCHEMBL4294249 | 0.83 | HSD11B1 (0.45) | MRGPRX4KMONOTUMKDR | |
| Hydrochloric Acid SCHEMBL6369011 | 0.83 | TSHR (0.57) | TSHRNOTUMPDK1SRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| EP-0780371-B1 | 2-Alkylmercapto-4-trifluoromethyl-benzoic acid esters as well as a process for their preparation | CLARIANT GMBH (DE) | 2000-08-23 | — | — | EP | claimed |
| EP-0780371-A2 | 2-Alkylmercapto-4-trifluoromethyl-benzoic acid esters as well as a process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-25 | — | — | EP | claimed |
| US-20250288587-A1 | Methods of Treating Fibrosis | ATHIRA PHARMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250275975-A1 | Methods of Treating Neuropathies | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250161308-A1 | Methods of Treating Covid-Related Disorders | ATHIRA PHARMA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4518866-A1 | METHODS OF TREATING FIBROSIS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518865-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250041307-A1 | Uses of Bicyclic Compounds for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20050054637-A1 | Substituted piperazine cyclohexane carboxilic acid amides and the use thereof | PASCAL ENGINEERING CORPORATION (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1436273-A1 | SUBSTITUTED PIPERAZINE CYCLOHEXANE CARBOXILIC ACID AMIDES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| CN-1148357-C | Triazole and imidazole derivative | - | 2004-05-05 | — | — | CN | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003033484-A1 | SUBSTITUTED PIPERAZINE CYCLOHEXANE CARBOXILIC ACID AMIDES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| CN-1281852-A | Triazole and imidazole derivative | HOFFMANN LA ROCHE (CH) | 2001-01-31 | — | — | CN | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041307-A1 | Uses of Bicyclic Compounds for the Treatment of Diseases | HDGF, HGF, GLS2 | TSHR 1465/4885MRGPRX4 3719/4885KMO 2878/4885 |
| US-20250288587-A1 | Methods of Treating Fibrosis | HDGF, HGF, MMP1 | TSHR 3464/4885MRGPRX4 1244/4885KMO 4466/4885 |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | HGF, HDGF, NGF | TSHR 3207/4885MRGPRX4 1252/4885KMO 2337/4885 |
| US-20050054637-A1 | Substituted piperazine cyclohexane carboxilic acid amides and the use thereof | AADAC, HCAR2, EGLN2 | TSHR 2392/4885MRGPRX4 2957/4885KMO 1596/4885 |
| US-20250275975-A1 | Methods of Treating Neuropathies | NGF, HGF, HDGF | TSHR 1858/4885MRGPRX4 1476/4885KMO 3578/4885 |
| US-20250161308-A1 | Methods of Treating Covid-Related Disorders | HGF, ACE2, MET | TSHR 1960/4885MRGPRX4 660/4885KMO 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.